header logo image

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

August 7th, 2024 2:40 am

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion –

Here is the original post:
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick